The role of second-trimester serum screening in the post-first-trimester screening era

Clinics in Laboratory Medicine

Volumn 30, Issue 3, 2010, Pages 667-676

  Shamshirsaz, Alireza A ^a   Benn Peter, P ^a   Egan, James F X ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Aneuploidy; Diagnosis; Down syndrome; Maternal serum; Prenatal; Screening; Ultrasound

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; ESTRIOL; INHIBIN A; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

AMNIOCENTESIS; BLOOD ANALYSIS; CHORION VILLUS SAMPLING; CLINICAL PROTOCOL; DIAGNOSTIC ACCURACY; DISEASE MARKER; DOWN SYNDROME; EARLY DIAGNOSIS; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GENETIC RISK; HUMAN; INTERMETHOD COMPARISON; INVASIVE PROCEDURE; MATERNAL AGE; MATERNAL SERUM; NUCHAL TRANSLUCENCY MEASUREMENT; PATIENT SATISFACTION; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECOND TRIMESTER PREGNANCY; UNITED STATES; BLOOD; FEMALE; FETAL DISEASES; MASS SCREENING; PREGNANCY; PRENATAL DIAGNOSIS; PROCEDURES;

BIOLOGICAL MARKERS; DOWN SYNDROME; FEMALE; FETAL DISEASES; HUMANS; MASS SCREENING; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS;

EID: 77954807027     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2010.04.013     Document Type: Review

References (43)

1. Korenberg J.R., Chen X.N., Schipper R., et al. Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc Natl Acad Sci U S A 1994, 91:4997-5001.
2. Mathews T.J., Hamilton B.E. Mean age of mother, 1970-2000. Natl Vital Stat Rep 2002, 51:1-13.
3. Egan J.F., Benn P., Borgida A.F., et al. Efficacy of screening for fetal Down syndrome in the United States from 1974 to 1997. Obstet Gynecol 2000, 96(6):979-985.
4. Martin J.A., Hamilton B.E., Sutton P.D., et al. Births: final data for 2002. Natl Vital Stat Rep 2003, 52:1-113.
5. National Vital Statistics Reports Centers for Disease Control and Prevention, Atlanta, GA Available at:, Accessed May 30, 2010. http://www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56_06.pdf.
6. Odibo A.O., Stamilio D.M., Nelson D.B., et al. A cost-effectiveness analysis of prenatal screening strategies for Down syndrome. Obstet Gynecol 2005, 106:562-568.
7. Cuckle H., Benn P.A. Multi-marker maternal serum screening for chromosome abnormalities. Genetic disorders and the fetus. 6th edition 2010, 771-818. Wiley-Blackwell, Chichester. A. Milunsky, J.A. Milunsky (Eds.).
8. ACOG Committee on Practice Bulletin ACOG practice bulletin NO.77: screening for fetal chromosomal abnormalities. Obstet Gynecol 2007, 109:217-227.
9. Snijders R.J., Noble P., Sebire N., et al. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998, 352:343-346.
10. Wald N.J., Rodeck C., Hackshaw A.K., et al. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003, 7:1-77.
11. Malone F.D., Canick J.A., Ball R.H., et al. First and Second Trimester Evaluation of Risk for Fetal Aneuploidy (FASTER): principal results of the NICHD multicenter Down syndrome screening study. N Engl J Med 2005, 353:2001-2011.
12. Merkatz I.R., Nitowsky H.M., Macri J.N., et al. An association between low maternal serum alpha-fetoprotein and fetal chromosome abnormalities. Am J Obstet Gynecol 1984, 148:886-894.
13. Cuckle H.S., Wald N.J., Lindenbaum R.H. Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. Lancet 1984, 1:926-929.
14. Milunsky A., Alpert E. Maternal serum AFP secreening. N Engl J Med 1978, 298(13):738-739.
15. Crandall B.F., Robinson L., Grau P. Risks associated with an elevated maternal serum alpha-fetoprotein level. Am J Obstet Gynecol 1991, 165(3):581-586.
16. Bogart M.H., Pandian M.R., Jones O.W. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 1987, 7:623-630.
17. Macri J.N., Kasturi R.V., Krantz D.A., et al. Maternal serum Down syndrome screening: free beta-protein is a more effective marker than human chorionic gonadotropin. Am J Obstet Gynecol 1990, 163(4 Pt 1):1248-1253.
18. Lambert-Messerlian G., Pinar H., Rubin L.P., et al. Second-trimester maternal serum markers in twin pregnancies with complete mole, report of 2 cases. Pediatr Dev Pathol 2005, 8:230-234.
19. Paradinas F.J., Sebire N.J., Fisher R.A., et al. Pseudo-partial moles, placental stem vessel hydrops and the association with Beckwith-Wiedemann syndrome and complete moles. Histopathology 2001, 39:447-454.
20. Benn P.A., Gainey A., Ingardia C.J., et al. Second trimester maternal serum analytes in triploid pregnancies, correlation with phenotype and sex chromosome complement. Prenat Diagn 2001, 21(8):680-686.
21. Saller D.N., Canick J.A., Schwartz S., et al. Multiple-marker screening in pregnancies with hydropic and nonhydropic Turner syndrome. Am J Obstet Gynecol 1992, 167(4 Pt 1):1021-1024.
22. Lambert-Messerlian G.M., Saller D.N., Tumber M.B., et al. Second-trimester maternal serum inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops. Prenat Diagn 1998, 18(10):1061-1067.
23. Canick J.A., Knight G.J., Palomaki G.E., et al. Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. Br J Obstet Gynaecol 1988, 95:330-333.
24. Kashork C.D., Sutton V.R., Fonda Allen J.S., et al. Low or absent unconjugated estriol in pregnancy, an indicator for steroid sulfatase deficiency detectable by fluorescence in situ hybridization and biochemical analysis. Prenat Diagn 2002, 22(11):1028-1032.
25. Bradley L.A., Palomaki G.E., Knight G.J., et al. Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Opitz (RSH) syndrome fetuses. Am J Med Genet 1999, 82(4):355-358.
26. Craig W.Y., Haddow J.E., Palomaki G.E., et al. Major fetal abnormalities associated with positive screening test for Smith-Lemli-Opitz syndrome (SLOS). Prenat Diagn 2007, 27:409-414.
27. Van Lith J.M., Pratt J.J., Beekhuis J.R., et al. Second-trimester maternal serum immunoreactive inhibin as a marker for fetal Down's syndrome. Prenat Diagn 1992, 12(10):801-806.
28. Wallace E.M., Grant V.E., Swanston I.A., et al. Evaluation of maternal serum dimeric inhibin A as a first-trimester marker of Down's syndrome. Prenat Diagn 1995, 15(4):359-362.
29. Brambati B., Lanzani A., Tului L. Ultrasound and biochemical assessment of first trimester pregnancy. The embryo: normal and abnormal development and growth 1991, 181-194. Springer-Verlag, New York. M. Chapman, G. Grudzinskas, T. Chard (Eds.).
30. Nicolaides K.H., Azar G., Byrne D., et al. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. Br Med J 1992, 304(6831):867-869.
31. Snijders R.J., Thom E.A., Zachary J.M., et al. First-trimester trisomy screening: nuchal translucency measurement training and quality assurance to correct and unify technique. Ultrasound Obstet Gynecol 2002, 19(4):353-359.
32. Montenegro N., Matias A., Areias J.C., et al. Increased fetal nuchal translucency, possible involvement of early cardiac failure. Ultrasound Obstet Gynecol 1997, 10(4):265-268.
33. Fang Y.M.V., Benn P., Campbell W., et al. Down syndrome screening in the United States in 2001 and 2007: a survey of maternal-fetal medicine specialists. Am J Obstet Gynecol 2009, 201:97. e1-5.
34. Benn P.A., Egan J.F. Second trimester prenatal ultrasound and screening for Down syndrome. Prenat Diagn 2007, 27(9):884.
35. Wald N.J., Watt H.C., Hackshaw A.K. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters. N Engl J Med 1999, 341:461-467.
36. Canick J.A., MacRae A.R. Second trimester serum markers. Semin Perinatol 2005, 29:203-208.
37. Marteau T.M., Kidd J., Michie S., et al. Anxiety, knowledge and satisfaction in women receiving false positive results on routine prenatal screening: a randomized controlled trial. J Psychosom Obstet Gynaecol 1993, 14:185-196.
38. Wapner R., Thom E., Simpson J.L., et al. First-trimester screening for trisomies 21 and 18. N Engl J Med 2003, 349:1405-1413.
39. Cuckle H., Benn P., Wright D. Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parameters. Semin Perinatol 2005, 29:252-257.
40. Benn P., Donnenfeld A.E. Sequential Down syndrome screening: the importance of first and second trimester test correlations when calculating risk. J Genet Couns 2005, 14(6):409-413.
41. Benn P., Wright D., Cuckle H. Practical strategies in contingent sequential screening for Down syndrome. Prenat Diagn 2005, 25:645-652.
42. Gekas J., Gagné G., Bujold E., et al. Comparison of different strategies in prenatal screening for Down's syndrome: cost effectiveness analysis of computer simulation. BMJ 2009, 338:b138.
43. Aagaard-Tillery K.M., Malone F., Nyberg D., et al. Role of second-trimester genetic sonography after Down syndrome screening. Obstet Gynecol 2009, 114:1189-1196.